NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
Sellas Life Sciences Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)